6.2.3. metastatic disease (stage ii c iii). 6.2.3.1. primary chemotherapy 6.2.3.1.1. good-prognosis risk group - seminomatous germ cell tumour metastatic seminoma, cisplatin-based regimen used. cisplatin-based combination chemotherapy shown superior efficacy carboplatin-based regimens . standard regimen good-risk seminoma three, twenty-one days cycles bep (table 6). alternatively, ep x 4 may considered especially bleomycin contraindicated . achieves similar response rates may slightly higher risk relapse. post-chemotherapy masses managed described section 6.5.2. 6.2.3.1.2. intermediate-prognosis risk group - seminomatous germ cell tumour patients intermediate-risk seminoma, bep x 4 standard regimen. bleomycin contraindicated combination etoposide, cisplatin, ifosfamide (vip) given. rct focused specifically rare group patients (see table 4). 6.2.3.1.3. good-prognosis risk group - non-seminomatous germ cell tumour standard regimen good-risk non-seminoma bep x 3 (table 6) . rct support equivalence three five-day regimes three four cycles bep projected two-years pfs. three-day regimes associated increased toxicity . based data bep x 3 five-day regimen strongly recommended good-prognosis risk group. two rcts support superiority bep x 3 regimes schedule intensities . rct suggested ep used, mortality rate twice bep, although difference reach statistical significance . patients clear contraindication bleomycin may receive ep x 4 . cases omission bleomycin recommended. information regarding chemotherapy protocols, please visit eau guidelines website:https://uroweb.org/guidelines/testicular-cancer/publications-appendices 6.2.3.1.4. intermediate-prognosis risk group - non-seminomatous germ cell tumour standard regimen bep x 4 . four cycles vip similar efficacy myelotoxic . four cycles vip including primary g-csf prophylaxis applied patients contraindications bleomycin. 6.2.3.1.5. poor-prognosis risk group - non-seminomatous germ cell tumour standard regimen four cycles bep. four cycles vip similar efficacy, myelotoxic . four cycles vip including primary granulocyte colony stimulating factor (g-csf) prophylaxis applied patients contraindications bleomycin . serum tumour marker decline prospectively confirmed predictor response cisplatin chemotherapy metastatic germ cell tumour patients. patients inadequate tumour marker decline first second cycle bep represent prognostically inferior subgroup . several ways calculate tumour marker decline kinetics example available at: https://www.gustaveroussy.fr/calculation-tumor/nsgct.html. rct demonstrated improved pfs intensifying treatment dose-dense chemotherapy patients early unfavourable tumour marker decline . trial powered estimate os differences. based results trial, patients unfavourable tumour marker decline bep x 1 switched intensive (dose-dense) chemotherapy regimen . additional patient groups unfavourable prognosis standard treatment primary mediastinal non-seminoma patients brain metastases initial diagnosis . may also candidates upfront intensified treatment, preferably prospective study. rcts, primary high-dose chemotherapy (hdct) subsequent autologous stem cell transplantation shown os benefit overall poor-prognosis patient population rcts . selected patients, primary mediastinal nonseminoma, poor survival following standard dose chemotherapy . may derive benefit primary hdct , preferably within prospective protocol. better outcomes reported intermediate poor prognosis patients treated high-volume centres [183-185]. due unfavourable survival, poor-prognosis patients managed centres interdisciplinary germ cell tumour expertise treated ongoing prospective trials registries, whenever possible. general recommendations treatment modifications patients poor performance status (karnofsky < 50%) extended liver infiltration (> 50%), although two small patient series indicate initial cycle dose-reduced therapy may reduce acute mortality without compromising long-term outcomes. number subsequent cycles full-dose therapy should, however, reduced initial low-dose induction cycle . patients widespread pulmonary metastases risk pulmonary haemorrhage subsequent acute respiratory distress syndrome (ards) induction chemotherapy. reduce risk, primary cytoreductive induction chemotherapy ep two three days administered, followed first cycle standard chemotherapy risk ards passed (typically ten days) . table 6: level evidence prognostic group treatment prognostic group igcccgtreatmentlegood (sgct nsgct)bep x 3 ep x 41bintermediate (sgct nsgct)bep x 4 vip x 41bpoor (nsgct)bep x 4 vip x 4 favourable marker decline1bdose escalation selected cases inadequate serum tumour marker decline1b 6.2.3.1.6. prevention thromboembolism events chemotherapy rcts assessed risks benefits thromboprophylaxis ambulatory cancer patients receiving chemotherapy report relative risk reduction 30-60% venous thromboembolic events (vte) cost doubling bleeding risk [187-190]. based results, recent american society clinical oncology (asco) clinical practice guideline update recommends thromboprophylaxis apixaban, rivaroxaban, low molecular weight heparin (lmwh) cancer patients high risk vte low risk bleeding . metastatic germ cell tumour (mgct) patients under-represented trials thus, clear whether recommendation applies group although retrospective data suggests similar efficacy vte prophylaxis . eau guideline panel discussed recommendation regarding thromboprophylaxis. members agreed men mgcts undergoing cisplatin-based chemotherapy high-risk vte, exception choriocarcinoma high volume extra-peritoneal disease, low risk bleeding. given apparent high vte incidence* non-validated vte risk factors, panel preferences divided panel members favoured thromboprophylaxis men panel members restricted thromboprophylaxis men certain risk factors. additionally, majority panel agreed central venous-access device avoided whenever possible represents modifiable risk factor, remained significantly associated vte multivariable risk-prediction model . *for information regarding prevention thromboembolism events chemotherapy, please see appendix 2, available online https://uroweb.org/guidelines/testicular-cancer/publications-appendices. 6.2.3.1.7. summary evidence recommendations prevention thromboembolism events chemotherapy summary evidencelethromboembolic events occur frequently male patients gcts receiving chemotherapy young males chemotherapy cancers.2bretrospective studies identified multiple risk factors development thromboembolic events including increasing stage, size retroperitoneal lymph nodes different cut-offs, khorana score > 3 indwelling vascular access device (only modifiable risk factor).2b recommendationsstrength ratingbalance individual patientsâ€™ potential benefits risks thromboprophylaxis first-line chemotherapy men metastatic germ cell tumours.weakavoid use central venous-access devices first-line chemotherapy whenever possible.weak